Biopsy Quotas: Ethical Implications of Financial Incentives and Penalties on Dermatologic Care Providers

Abstract

The evolution of health care payment models has profoundly influenced clinical practices and physician decision-making. Although fee-for-service models incentivize procedural volume, systems based on relative value units have introduced standardized metrics to compensate physicians based on care complexity and workload. As corporations increasingly own health care, financial incentives such as relative value units and procedural quotas raise ethical concerns. Quotas intended to boost efficiency and profitability may prompt corporate entities to pressure clinicians to meet procedural targets, potentially prioritizing financial performance over patient welfare. Such pressures risk leading to overtreatment and unnecessary procedures, challenging the principles of nonmaleficence and beneficence, especially when less invasive or noninvasive alternatives are clinically viable. Ethical frameworks, including the American Medical Association Code of Medical Ethics, emphasize the need for compensation models that align with clinical judgment and support patient-centered care.